Affiliation
University of Texas Health Science Center; Foundation for Advancement of Veteran's Health and Research; Sandwell and West Birmingham NHS TrustPublication date
2021-08-18
Metadata
Show full item recordAbstract
Antidiabetic medications that improve glycemic control as well as cardiovascular outcomes will be the mainstay of treatment for type 2 diabetes moving forward. This article reviews the beneficial effects of the thiazolidinedione pioglitazone of ameliorating hyperglycemia and improving cardiovascular risk factors. While the newer sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide 1 receptor agonist drug classes have confirmed cardiovascular benefits, pioglitazone also has been shown to reduce major adverse cardiovascular events, in both people with type 2 diabetes and nondiabetic subjects with insulin resistance. Adverse effects associated with pioglitazone can be mitigated by its use at a lower dose and in combination with antidiabetic agents from other drug classes.Citation
Tripathy D, Solis-Herrera C, Ryder REJ. Cardioprotective Effects of Pioglitazone in Type 2 Diabetes. Diabetes Spectr. 2021 Aug;34(3):243-247.Type
ArticlePMID
34511850Publisher
American Diabetes Associationae974a485f413a2113503eed53cd6c53
10.2337/ds20-0078